Pathological Features of COVID-19-Associated Liver Fibros

Bin Zhao,

DOI: https://doi.org/10.24966/cmph-1978/1000106

2022-06-22

Community Medicine & Public Health Care

Abstract:Most studies suggest that though mild derangements of liver function may be experienced by most COVID-19 patients but significant liver injury is not common

What problem does this paper attempt to address?

Clinical Features of COVID-19-Related Liver Damage

Zhenyu Fan,Liping Chen,Jun Li,Cheng Tian,Yajun Zhang,Shaoping Huang,Zhanju Liu,Jilin Cheng

DOI: https://doi.org/10.1101/2020.02.26.20026971

2020-01-01

SSRN Electronic Journal

Abstract:BACKGROUND: A recent outbreak of SARS-CoV-2 infection occurs mainly in China, with rapidly increasing the number of cases (namely COVID-19). Abnormal liver functions are frequently present in these patients, here we aimed to clarify the clinical features of COVID-19-related liver damage to provide some references for the clinical treatment. METHODS: In this retrospective, single-center study, we included all confirmed COVID-19 cases in Shanghai Public Health Clinical Center from January 20 to January 31, 2020. The outcomes were followed up until February 19, 2020. A total of 148 cases were analyzed for clinical features, laboratory parameters (including liver function tests), medications and the length of stay. FINDINGS: Of 148 confirmed SARS-CoV-2-infected patients, 49.3% were females and 50.7% were males. The median age was 50.5 years (interquartile range, 36-64). Patients had clinical manifestations of fever (70.1%), cough (45.3%), expectoration (26.7%) at admission. 75 patients (50.7%) showed abnormal liver functions at admission, characterized by an increased of alt, ast, GGT, AKP. Patients (n = 75) who had elevated liver function index were more likely to have a moderate-high degree fever (44% vs 27.4%; p = 0.035) and significantly present in male patients (62.67% vs 38.36%; p = 0.005). The numbers of CD4+ and CD8+ T cells were significantly lower in abnormal liver function group than those in normal liver function group. There was no statistical difference in prehospital medications between normal and abnormal liver function groups, while the utilization rate of lopinavir/ritonavir after admission was significantly higher in patients with emerging liver injury than that in patients with normal liver functions. Importantly, the emerging abnormal liver functions after admission caused a prolonged length of stay. INTERPRETATION: SARS-CoV-2 may cause the liver function damage and the Lopinavir/ritonavir should be applied carefully for the treatment of COVID-19.
Liver Injury in Patients with COVID-19: A Retrospective Study

Yun Feng,Yaping Liu,Qian Zhao,Jiao Zhu,Xiaona Kang,Chen Mi,Peijie Li,Weizhi Li,Guifang Lu,Ai Jia,Shuixiang He,Hongxia Li

DOI: https://doi.org/10.7150/ijms.81214

2023-01-01

International Journal of Medical Sciences

Abstract:Objectives: The objective of this study is to explore the incidence, characteristics, risk factors, and prognosis of liver injury in patients with COVID-19. Methods: We collected clinical data of 384 cases of COVID-19 and retrospectively analyzed the incidence, characteristics, and risk factors of liver injury of the patients. In addition, we followed the patient two months after discharge. Results: A total of 23.7% of the patients with COVID-19 had liver injury, with higher serum AST (P < 0.001), ALT (P < 0.001), ALP (P = 0.004), GGT (P < 0.001), total bilirubin (P = 0.002), indirect bilirubin (P = 0.025) and direct bilirubin (P < 0.001) than the control group. The median serum AST and ALT of COVID-19 patients with liver injury were mildly elevated. Risk factors of liver injury in COVID-19 patients were age (P = 0.001), history of liver diseases (P = 0.002), alcoholic abuse (P = 0.036), body mass index (P = 0.037), severity of COVID-19 (P < 0.001), C-reactive protein (P < 0.001), erythrocyte sedimentation rate (P < 0.001), Qing-Fei-Pai-Du-Tang treatment (P = 0.032), mechanical ventilation (P < 0.001), and ICU admission (P < 0.001). Most of the patients (92.3%) with liver injury were treated with hepatoprotective drugs. 95.6% of the patients returned to normal liver function tests at 2 months after discharge. Conclusions: Liver injury was commen in COVID-19 patients with risk factors, most of them have mild elevations in transaminases, and conservative treatment has a good short-term prognosis.

medicine, general & internal
Liver Diseases in COVID-19: Etiology, Treatment and Prognosis

Jian Wu,Shu Song,Hong-Cui Cao,Lan-Juan Li

DOI: https://doi.org/10.3748/wjg.v26.i19.2286

IF: 5.374

2020-01-01

World Journal of Gastroenterology

Abstract:In December 2019, a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in Wuhan, China causing coronavirus disease-2019 (COVID-19).Numerous studies have shown varying degrees of liver damage in patients infected with SARS-CoV-2.However, in previous case studies of COVID-19, the exact cause of liver injury has not been clearly elucidated, nor is there clear evidence of the interaction between liver injury and COVID-19.This study will analyze the causes of liver injury in COVID-19 and the influence of liver-related complications on the treatment and prognosis of COVID-19.
Liver diseases in COVID-19: Etiology, treatment and prognosis.

Jian Wu,Shu Song,Hong-Cui Cao,Lan-Juan Li

DOI: https://doi.org/10.3748/wjg.v26.i19.2286

IF: 5.374

2020-01-01

World Journal of Gastroenterology

Abstract:In December 2019, a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in Wuhan, China causing coronavirus disease-2019 (COVID-19). Numerous studies have shown varying degrees of liver damage in patients infected with SARS-CoV-2. However, in previous case studies of COVID-19, the exact cause of liver injury has not been clearly elucidated, nor is there clear evidence of the interaction between liver injury and COVID-19. This study will analyze the causes of liver injury in COVID-19 and the influence of liver-related complications on the treatment and prognosis of COVID-19.
Corona Virus Disease 2019-Associated Liver Injury in Cold Regions

Shima Tang,Fen Zhang,Qiuhong Liu,Lanjuan Li

DOI: https://doi.org/10.2478/fzm-2022-0026

2022-01-01

Frigid Zone Medicine

Abstract:The corona virus disease 2019 (COVID-19) pandemic has created a global health and economic crisis. Our studies uncovered that in addition to respiratory symptoms, liver damage is also common in COVID-19 patients; however, the cause of liver damage has not been fully elucidated. In this article, we summarize the clinical manifestations and pathological features of COVID-19 reported in published relevant studies and delineate the etiology and pathogenesis of COVID-19-related liver injury. We speculate that cold stimulation may be associated with COVID-19-related liver injury, which should be considered in clinical decision-making and treatment of COVID-19 in cold regions.
COVID-19-associated liver injury: Adding fuel to the flame

Yingqian Wang,Min Shen,Yujia Li,Jiangjuan Shao,Feng Zhang,Mei Guo,Zili Zhang,Shizhong Zheng

DOI: https://doi.org/10.1002/cbf.3883

Abstract:COVID-19 is mainly characterized by respiratory disorders and progresses to multiple organ involvement in severe cases. With expansion of COVID-19 and SARS-CoV-2 research, correlative liver injury has been revealed. It is speculated that COVID-19 patients exhibited abnormal liver function, as previously observed in the SARS and MERS pandemics. Furthermore, patients with underlying diseases such as chronic liver disease are more susceptible to SARS-CoV-2 and indicate a poor prognosis accompanied by respiratory symptoms, systemic inflammation, or metabolic diseases. Therefore, COVID-19 has the potential to impair liver function, while individuals with preexisting liver disease suffer from much worse infected conditions. COVID-19 related liver injury may be owing to direct cytopathic effect, immune dysfunction, gut-liver axis interaction, and inappropriate medication use. However, discussions on these issues are infancy. Expanding research have revealed that angiotensin converting enzyme 2 (ACE2) expression mediated the combination of virus and target cells, iron metabolism participated in the virus life cycle and the fate of target cells, and amino acid metabolism regulated immune response in the host cells, which are all closely related to liver health. Further exploration holds great significance in elucidating the pathogenesis, facilitating drug development, and advancing clinical treatment of COVID-19-related liver injury. This article provides a review of the clinical and laboratory hepatic characteristics in COVID-19 patients, describes the etiology and impact of liver injury, and discusses potential pathophysiological mechanisms.
SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19

Yijin Wang,Shuhong Liu,Hongyang Liu,Wei Li,Fang Lin,Lina Jiang,Xi Li,Pengfei Xu,Lixin Zhang,Lihua Zhao,Yun Cao,Jiarui Kang,Jianfa Yang,Ling Li,Xiaoyan Liu,Yan Li,Ruifang Nie,Jinsong Mu,Fengmin Lu,Shousong Zhao,Jiangyang Lu,Jingmin Zhao

DOI: https://doi.org/10.1016/j.jhep.2020.05.002

IF: 25.7

2020-10-01

Journal of Hepatology

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>Liver enzyme abnormality is common in patients with coronavirus disease 2019 (COVID-19). Whether or not SARS-CoV-2 infection can lead to liver damage <em>per se</em> remains unknown. Here we reported the clinical characteristics and liver pathological manifestations of COVID-19 patients with liver enzyme abnormality.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>We received 156 patients diagnosed of COVID-19 from two designated centers in China, and compared clinical features between patients with elevated aminotransferase or not. Postmortem liver biopsies were obtained from two cases who had elevated aminotransferase. We investigated the patterns of liver impairment by electron microscopy, immunohistochemistry, TUNEL assay, and pathological studies.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>64 of 156 (41.0%) COVID-19 patients had elevated aminotransferase. The median levels of ALT were 50 U/L vs. 19 U/L, respectively, AST were 45.5 U/L vs. 24 U/L, respectively in abnormal and normal aminotransferase groups. The liver enzyme abnormality was associated with disease severity, as well as a series of laboratory tests including higher A-aDO2, higher GGT, lower albumin, decreased CD4+ T cells and B lymphocytes. Ultrastructural examination identified typical coronavirus particles characterized by spike structure in cytoplasm of hepatocytes in two COVID-19 cases. SARS-CoV-2 infected hepatocytes displayed conspicuous mitochondrial swelling, endoplasmic reticulum dilatation, and glycogen granule decrease. Histologically, massive hepatic apoptosis and a certain binuclear hepatocytes were observed. Taken together, both ultrastructural and histological evidence indicated a typical lesion of viral infection. Immunohistochemical results showed scanty CD4+ and CD8+ lymphocytes. No obvious eosinophil infiltration, cholestasis, fibrin deposition, granuloma, massive central necrosis, or interface hepatitis were observed.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>SARS-CoV-2 infection in liver is a crucial cause of hepatic impairment in COVID-19 patients. Hence, a surveillance of viral clearance in liver and long outcome of COVID-19 is required.</p>

gastroenterology & hepatology
Abnormal liver function on admission predicts severe outcomes in COVID-19 patients: a multicenter study (Preprint)

Xiu-Ping Zhang,Jiong Yu,Haibo Li,Wenquan Liang,Wentao Ni,Hongcui Cao,Rong Liu,Jie Liu,Lanjuan Li

DOI: https://doi.org/10.2196/preprints.23007

2020-01-01

Abstract:BACKGROUND Coronavirus disease 2019 (COVID-19) is a new infectious disease. Patients with mild COVID-19 have abnormal liver function at first blood examination upon admission.However, the association of abnormal liver function at admission in COVID-19 patients with severe outcomes is unclear. OBJECTIVE We aimed to elucidate the relationship between early abnormal liver function and COVID-19 severity. METHODS In this multicenter retrospective cohort study, patients with COVID-19 admitted to the 42 hospitals in Zhejiang province were enrolled. Clinical and pathological data of these patients were retrospectively analyzed. RESULTS A total of 963 patients meeting the inclusion criteria with mild COVID-19 on admission were enrolled. The occurrence of severe outcomes positively correlated with elevated aspartate aminotransferase (AST), alanine aminotransferase (ALT) and total bilirubin (TB) (P<0.001, P<0.008, and P=0.053, respectively). The probabilities of severe outcomes in patients with normal AST, ALT and TB levels were 13%, 21.3%, and 6.1%, respectively. In contrast, the probabilities were 34.8%, 34.8%, and 26.1%, respectively, in patients with elevated levels of injury indicators. After adjusting for confounding factors, in contrast to patients without liver dysfunction, patients with elevated AST, ALT and TB tended to have a higher risk of severe outcomes [HR (95% CI): 2.82 (1.49,5.35), 2.05 (1.08,3.88) and 3.21 (1.58,6.55), respectively]. CONCLUSIONS This study found for the first time that abnormal liver function in COVID-19 patients on admission was related to severe outcomes. Clinicians should closely monitor and pay attention to changes in patients’ conditions to prevent the occurrence of severe outcomes.
Clinical Features of COVID-19-Related Liver Functional Abnormality

Zhenyu Fan,Liping Chen,Jun Li,Xin Cheng,Jingmao Yang,Cheng Tian,Yajun Zhang,Shaoping Huang,Zhanju Liu,Jilin Cheng

DOI: https://doi.org/10.1016/j.cgh.2020.04.002

IF: 13.576

2020-06-01

Clinical Gastroenterology and Hepatology

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background & Aims</h3><p>Some patients with SARS-CoV-2 infection have abnormal liver function. We aimed to clarify the features of COVID-19-related liver damage to provide references for clinical treatment.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>We performed a retrospective, single-center study of 148 consecutive patients with confirmed COVID-19 (73 female, 75 male; mean age, 50 years) at the Shanghai Public Health Clinical Center from January 20 through January 31, 2020. Patient outcomes were followed until February 19, 2020. Patients were analyzed for clinical features, laboratory parameters (including liver function tests), medications, and length of hospital stay. Abnormal liver function was defined as increased levels of alanine and aspartate aminotransferase, gamma glutamyltransferase, alkaline phosphatase, and total bilirubin.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Fifty-five patients (37.2%) had abnormal liver function at hospital admission; 14.5% of these patients had high fever (14.5%), compared with 4.3% of patients with normal liver function (<em>P</em>=.027). Patients with abnormal liver function were more likely to be male, and had higher levels of procalcitonin and C-reactive protein. There was no statistical difference between groups in medications taken before hospitalization; a significantly higher proportion of patients with abnormal liver function (57.8%) had received lopinavir/ritonavir after admission compared to patients with normal liver function (31.3%). Patients with abnormal liver function had longer mean hospital stays (15.09±4.79 days) than patients with normal liver function (12.76±4.14 days) (<em>P</em>=.021).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>More than one third of patients admitted to the hospital with SARS-CoV-2 infection have abnormal liver function, and this is associated with longer hospital stay. A significantly higher proportion of patients with abnormal liver function had received lopinavir/ritonavir after admission; these drugs should be given with caution.</p>

gastroenterology & hepatology
COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management

Penghui Li,Ying Liu,Ziqi Cheng,Xiaorui Yu,Yinxiong Li

DOI: https://doi.org/10.1016/j.biopha.2022.113568

2022-10-01

Abstract:Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become a global epidemic and poses a major threat to public health. In addition to COVID-19 manifesting as a respiratory disease, patients with severe disease also have complications in extrapulmonary organs, including liver damage. Abnormal liver function is relatively common in COVID-19 patients; its clinical manifestations can range from an asymptomatic elevation of liver enzymes to decompensated hepatic function, and liver injury is more prevalent in severe and critical patients. Liver injury in COVID-19 patients is a comprehensive effect mediated by multiple factors, including liver damage directly caused by SARS-CoV-2, drug-induced liver damage, hypoxia reperfusion dysfunction, immune stress and inflammatory factor storms. Patients with chronic liver disease (especially alcohol-related liver disease, nonalcoholic fatty liver disease, cirrhosis and hepatocellular carcinoma) are at increased risk of severe disease and death after infection with SARS-CoV-2, and COVID-19 aggravates liver damage in patients with chronic liver disease. This article reviews the latest SARS-CoV-2 reports, focusing on the liver damage caused by COVID-19 and the underlying mechanism, and expounds on the risk, treatment and vaccine safety of SARS-CoV-2 in patients with chronic liver disease and liver transplantation.

pharmacology & pharmacy,medicine, research & experimental
Pathological features of COVID-19-associated liver injury—a preliminary proteomics report based on clinical samples

Ling Leng,Ruiyuan Cao,Jie Ma,Luye Lv,Wei Li,Yunping Zhu,Zhihong Wu,Manli Wang,Yiwu Zhou,Wu Zhong

DOI: https://doi.org/10.1038/s41392-020-00406-1

IF: 39.3

2021-01-08

Signal Transduction and Targeted Therapy

Abstract:<p>Signal Transduction and Targeted Therapy, Published online: 08 January 2021; <a href="https://www.nature.com/articles/s41392-020-00406-1">doi:10.1038/s41392-020-00406-1</a></p>Pathological features of COVID-19-associated liver injury—a preliminary proteomics report based on clinical samples

biochemistry & molecular biology,cell biology
Preliminary Exploration of the Cause of Liver Disorders During Early Stages in COVID-19 Patients

Yuan Gao,Qi Li,Hongbo Shi,Yingmei Feng,Tong Zhang,Yu Chen,Lianchun Liang,Dexi Chen,Hao Wu,Ronghua Jin,Xiaojie Huang

DOI: https://doi.org/10.3389/fmed.2020.00501

IF: 3.9

2020-08-07

Frontiers in Medicine

Abstract:<b>Background:</b> Abnormal liver function is a common indication of coronavirus disease 2019 (COVID-19) patients. Two proposed mechanisms are liver injury mediated by angiotensin-converting enzyme 2 (ACE2) and the involvement of the systemic immune response. We investigated the role played by these to determine the cause of liver abnormality in the early stages of COVID-19. <b>Methods:</b> A cross-sectional study was conducted among confirmed cases of COVID-19 at Beijing Youan Hospital from January 21, 2020, to February 24, 2020. We compared clinical characteristics, viremia status, and cytokine profile on admission between patients with and without liver disorder. <b>Results:</b> Of the 44 COVID-19 patients analyzed, there were no differences in the clinical symptoms and signs, disease severity, or computed tomography (CT) image features between the two groups. Lymphopenia was more common in the liver disorder group. Further, C-reactive protein levels were much higher in the hepatic disorder group, with significantly higher concentrations of IL-6, IL-10, and M-CSF. Viremia was detected in only 7% of patients. <b>Conclusions:</b> Due to the infrequency of viremia, ACE2-mediated viral hepatitis does not seem to account for the commonly observed liver disorders in COVID-19 patients. By contrast, a dysregulated immune response may be a crucial pathogenic factor for liver disorder in the early stages of COVID-19.

medicine, general & internal
Progress in the Clinical Features and Pathogenesis of Abnormal Liver Enzymes in Coronavirus Disease 2019

Haiyan Wu,Shuzhong Liu,Hesheng Luo,Mingkai Chen

DOI: https://doi.org/10.14218/JCTH.2020.00126

2021-01-01

Journal of Clinical and Translational Hepatology

Abstract:With the rapid development of research on coronavirus disease 2019 (COVID-19), more and more attention has been drawn to its damage to extrapulmonary organs. There are increasing lines of evidence showing that liver injury is closely related to the severity of COVID-19, which may have an adverse impact on the progression and prognosis of the patients. What is more, severe acute respiratory syndrome coronavirus-2 infection, cytokine storm, ischemia/hypoxia reperfusion injury, aggravation of the primary liver disease and drug-induced liver injury may all contribute to the hepatic damage in COVID-19 patients; although, the drug-induced liver injury, especially idiosyncratic drug-induced liver injury, requires further causality confirmation by the updated Roussel Uclaf Causality Assessment Method published in 2016. Up to now, there is no specific regimen for COVID-19, and COVID-19-related liver injury is mainly controlled by symptomatic and supportive treatment. Here, we review the clinical features of abnormal liver enzymes in COVID-19 and pathogenesis of COVID-19-related liver injury based on the current evidence, which may provide help for clinicians and researchers in exploring the pathogenesis and developing treatment strategies.
Clinical Features of Patients With COVID-19 With Nonalcoholic Fatty Liver Disease

Rui Huang,Li Zhu,Jian Wang,Leyang Xue,Longgen Liu,Xuebing Yan,Songping Huang,Yang Li,Xiaomin Yan,Biao Zhang,Tianmin Xu,Chunyang Li,Fang Ji,Fang Ming,Yun Zhao,Juan Cheng,Yinling Wang,Haiyan Zhao,Shuqin Hong,Kang Chen,Xiang-an Zhao,Lei Zou,Dawen Sang,Huaping Shao,Xinying Guan,Xiaobing Chen,Yuxin Chen,Jie Wei,Chuanwu Zhu,Chao Wu

DOI: https://doi.org/10.1002/hep4.1592

2020-01-01

Hepatology Communications

Abstract:Previous studies reported that coronavirus disease 2019 (COVID-19) was likely to result in liver injury. However, few studies investigated liver injury in patients with COVID-19 with chronic liver diseases. We described the clinical features in patients with COVID-19 with nonalcoholic fatty liver disease (NAFLD). Confirmed patients with COVID-19 from hospitals in 10 cities of Jiangsu Province, China, were retrospectively included between January 18, 2020, and February 26, 2020. The hepatic steatosis index (HSI) was used to defined NAFLD. A total of 280 patients with COVID-19 were enrolled. Eighty-six (30.7%) of 280 patients with COVID-19 were diagnosed as NAFLD by HSI. One hundred (35.7%) patients presented abnormal liver function on admission. The median alanine aminotransferase (ALT) levels (34.5 U/L vs. 23.0 U/L;P < 0.001) and the proportion of elevated ALT (>40 U/L) (40.7% vs. 10.8%;P < 0.001) were significantly higher in patients with NAFLD than in patients without NAFLD on admission. The proportion of elevated ALT in patients with NAFLD was also significantly higher than patients without NAFLD (65.1% vs. 38.7%;P < 0.001) during hospitalization. Multivariate analysis showed that age over 50 years (odds ratio [OR], 2.077; 95% confidence interval [CI], 1.183, 3.648;P = 0.011) and concurrent NAFLD (OR, 2.956; 95% CI, 1.526, 5.726;P = 0.001) were independent risk factors of ALT elevation in patients with COVID-19, while the atomized inhalation of interferon alpha-2b (OR, 0.402; 95% CI, 0.236, 0.683;P = 0.001) was associated with a reduced risk of ALT elevation during hospitalization. No patient developed liver failure or death during hospitalization. The complications and clinical outcomes were comparable between patients with COVID-19 with and without NAFLD.Conclusion:Patients with NAFLD are more likely to develop liver injury when infected by COVID-19. However, no patient developed severe liver-related complications during hospitalization.
Liver injury in severe COVID-19 infection: current insights and challenges

Nurshad Ali,Khaled Hossain

DOI: https://doi.org/10.1080/17474124.2020.1794812

2020-07-17

Abstract:The outbreak of COVID-19 is a serious health threat worldwide. Different degrees of liver injury or liver dysfunctions have been reported in patients with COVID-19 infection. However, currently, it remains unclear to what extent liver diseases should be considered as significant risk factors for the severity and mortality of COVID-19. Moreover, the mechanisms involved in liver injury in severe COVID-19 infection are not yet well understood.This review summarizes the current evidence on liver function abnormalities in COVID-19 patients and the effects of preexisting liver disease on the disease severity. This review also illustrates the possible underlying mechanisms linking COVID-19 to liver injury, as well as provides recommendations to prevent liver damage in COVID-19 infection.The elevated levels of ALT, AST, GGT and bilirubin are common in more severe patients than non-severe or mild COVID-19 patients. Patients with preexisting medical conditions including chronic hepatic diseases are at higher risk for severe illness from COVID-19 infection. The drug's effects, possible viral inclusion in liver cells, systemic inflammation and hypoxia are potential causes of liver injury in severe COVID-19. Nevertheless, further studies are needed focusing on the preexisting hepatic diseases on prevention, treatment and outcome of COVID-19.

gastroenterology & hepatology
Liver impairment in COVID‐19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China

Yafei Zhang,Liang Zheng,Lan Liu,Mengya Zhao,Jun Xiao,Qiu Zhao

DOI: https://doi.org/10.1111/liv.14455

IF: 8.754

2020-04-28

Liver International

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>The SARS‐CoV‐2 pandemic is an ongoing global health emergency. The aim of our study was to investigate the changes of liver function and its clinical significance in COVID‐19 patients.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Method</h3><p>This retrospective, single‐center study was conducted on 115 confirmed cases of COVID‐19 in Zhongnan hospital of Wuhan University from Jan 18 to Feb 22, 2020. Liver function and related indexes were analyzed to evaluate its relationship with disease progression in COVID‐19 patients.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Part of the COVID‐19 patients presented with varying degrees of abnormality in liver function indexes. However, the levels of ALT, AST, TBIL, GGT and LDH in COVID‐19 patients were not significantly different in compared with hospitalized community‐acquired pneumonia patients, and the levels of albumin is even significantly higher. Levels of ALT, AST, TBIL, LDH and INR showed statistically significant elevation in severe COVID‐19 cases compared with that in mild cases. However, the clinical significance of the elevation is unremarkable. Majority of severe COVID‐19 patients showed significantly decreasing in albumin level and continuously decreasing in the progress of illness. Most of the liver function indexes in COVID‐19 patients were correlated with CRP and NLR, the markers of inflammation. Logistic regression analysis further identified NLR as the independent risk factor for severe COVID‐19, as well as age.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Although abnormalities of liver function indexes are common in COVID‐19 patients, the impairment of liver function is not a prominent feature of COVID‐19, and also may not have serious clinical consequences.</p></section>

gastroenterology & hepatology
Pathophysiological mechanisms of liver injury in COVID‐19

Alexander D. Nardo,Mathias Schneeweiss‐Gleixner,May Bakail,Emmanuel D. Dixon,Sigurd F. Lax,Michael Trauner

DOI: https://doi.org/10.1111/liv.14730

IF: 8.754

2020-11-29

Liver International

Abstract:<p>The recent outbreak of coronavirus disease 2019 (COVID‐19), caused by the Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) has resulted in a world‐wide pandemic. Disseminated lung injury with development of acute respiratory distress syndrome (ARDS) is the main cause of mortality in COVID‐19. Although liver failure does not seem to occur in the absence of preexisting liver disease, hepatic involvement in COVID‐19 may correlate with overall disease severity and serve as prognostic factor for development of ARDS. The spectrum of liver injury in COVID‐19 may range from direct infection by SARS‐CoV‐2, indirect involvement by systemic inflammation, hypoxic changes, iatrogenic causes such as drugs and ventilation to exacerbation of underlying liver disease. This concise review discusses the potential pathophysiological mechanisms for SARS‐CoV‐2 hepatic tropism as well as acute and possibly long‐term liver injury in COVID‐19.</p>

gastroenterology & hepatology
Implications of liver injury in risk-stratification and management of patients with COVID-19

Jiaofang Shao,Yuan Liang,Yan Li,Rong Ding,Mengyan Zhu,Wenhua You,Ziyu Wang,Bin Huang,Min Wu,Tingting Zhang,Kening Li,Wei Wu,Lingxiang Wu,Qianghu Wang,Xinyi Xia,Shukui Wang,Ling Lu

DOI: https://doi.org/10.1007/s12072-020-10123-0

IF: 9.029

2021-02-01

Hepatology International

Abstract:Infection with SARS-CoV-2 has been associated with liver dysfunction, aggravation of liver burden, and liver injury. This study aimed to assess the effects of liver injuries on the clinical outcomes of patients with COVID-19.

gastroenterology & hepatology
Liver Injury in COVID-19: Detection, Pathogenesis, and Treatment

Yue Cai,Li-Ping Ye,Ya-Qi Song,Xin-Li Mao,Li Wang,Yan-Zhi Jiang,Wei-Tao Que,Shao-Wei Li

DOI: https://doi.org/10.3748/wjg.v27.i22.3022

IF: 5.374

2021-01-01

World Journal of Gastroenterology

Abstract:In the early December 2019, a novel coronavirus named severe acute respiratory syndrome coronavirus 2 was first reported in Wuhan, China, followed by an outbreak that spread around the world. Numerous studies have shown that liver injury is common in patients with coronavirus disease 2019 (COVID-19), and may aggravate the severity of the disease. However, the exact cause and specific mechanism of COVID-associated liver injury needs to be elucidated further. In this review, we present an analysis of the clinical features, potential mechanisms, and treatment strategies for liver injury associated with COVID-19. We hope that this review would benefit clinicians in devising better strategies for management of such patients.
Liver injury in COVID-19: Clinical features, potential mechanisms, risk factors and clinical treatments

Shu-Wu Zhao,Yi-Ming Li,Yi-Lin Li,Chen Su

DOI: https://doi.org/10.3748/wjg.v29.i2.241

IF: 5.374

2023-01-14

World Journal of Gastroenterology

Abstract:The coronavirus disease 2019 (COVID-19) pandemic has been a serious threat to global health for nearly 3 years. In addition to pulmonary complications, liver injury is not uncommon in patients with novel COVID-19. Although the prevalence of liver injury varies widely among COVID-19 patients, its incidence is significantly increased in severe cases. Hence, there is an urgent need to understand liver injury caused by COVID-19. Clinical features of liver injury include detectable liver function abnormalities and liver imaging changes. Liver function tests, computed tomography scans, and ultrasound can help evaluate liver injury. Risk factors for liver injury in patients with COVID-19 include male sex, preexisting liver disease including liver transplantation and chronic liver disease, diabetes, obesity, and hypertension. To date, the mechanism of COVID-19-related liver injury is not fully understood. Its pathophysiological basis can generally be explained by systemic inflammatory response, hypoxic damage, ischemia-reperfusion injury, and drug side effects. In this review, we systematically summarize the existing literature on liver injury caused by COVID-19, including clinical features, underlying mechanisms, and potential risk factors. Finally, we discuss clinical management and provide recommendations for the care of patients with liver injury.

gastroenterology & hepatology

Pathological Features of COVID-19-Associated Liver Fibros

Clinical Features of COVID-19-Related Liver Damage

Liver Injury in Patients with COVID-19: A Retrospective Study

Liver Diseases in COVID-19: Etiology, Treatment and Prognosis

Liver diseases in COVID-19: Etiology, treatment and prognosis.

Corona Virus Disease 2019-Associated Liver Injury in Cold Regions

COVID-19-associated liver injury: Adding fuel to the flame

SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19

Abnormal liver function on admission predicts severe outcomes in COVID-19 patients: a multicenter study (Preprint)

Clinical Features of COVID-19-Related Liver Functional Abnormality

COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management

Pathological features of COVID-19-associated liver injury—a preliminary proteomics report based on clinical samples

Preliminary Exploration of the Cause of Liver Disorders During Early Stages in COVID-19 Patients

Progress in the Clinical Features and Pathogenesis of Abnormal Liver Enzymes in Coronavirus Disease 2019

Clinical Features of Patients With COVID-19 With Nonalcoholic Fatty Liver Disease

Liver injury in severe COVID-19 infection: current insights and challenges

Liver impairment in COVID‐19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China

Pathophysiological mechanisms of liver injury in COVID‐19

Implications of liver injury in risk-stratification and management of patients with COVID-19

Liver Injury in COVID-19: Detection, Pathogenesis, and Treatment

Liver injury in COVID-19: Clinical features, potential mechanisms, risk factors and clinical treatments